Citizens Reiterates Market Outperform on Sionna Therapeutics, Maintains $63 Price Target

Sionna Therapeutics

Sionna Therapeutics

SION

0.00

Citizens analyst Jonathan Wolleben reiterates Sionna Therapeutics (NASDAQ: SION) with a Market Outperform and maintains $63 price target.